Circassia successfully imports biotech frenzy to UK investors
Circassia, a UK biotech firm that is developing drugs to combat cat allergies, raised £210m through an IPO that brought the busy US sector to UK investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: